Neurogene (NGNE)

• Market cap: $241M
• 1 day: -2.41%
• 5 days: -5.10%
• 1 month: 7.43%
• 3 months: -27.42%
• 6 months: -55.92%
• Year to date: -29.23%
• 1 year: -46.78%
• 5 years: 7.28%
• 10 years: 7.28%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Employees: 91

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

1% more funds holding

Funds holding: 86 [Q3] → 87 (+1) [Q4]

8% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 25

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

29.95% less ownership

Funds ownership: 106.64% [Q3] → 76.69% (-29.95%) [Q4]

37% less capital invested

Capital invested by funds: $581M [Q3] → $368M (-$214M) [Q4]

44% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $5.52M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $55 240% upside
• Avg. target: $55 240% upside
• High target: $55 240% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 55 / 176 met price target

240% upside $55

Buy Reiterated

25 Nov 2024